Fig. 7: Accelerating preclinical development of lead compounds identified through EGS. | Nature Communications

Fig. 7: Accelerating preclinical development of lead compounds identified through EGS.

From: The Endo-GeneScreen platform identifies drug-like probes that regulate endogenous protein levels within physiological contexts

Fig. 7

a Top, Screen capture from DataWarrior exploration of SR-1815-like compounds within the full collection of small molecules. Bottom, Process for selecting 100 structurally similar SR-1815-like compounds. b Visualization of relative structural diversity among identified SR-1815-like compounds. Colored regions reflect different core motifs within SR-1815. c Relationship between molecular structure and SynGAP assay activity from 104 SR-1815-related compounds. The 104 compounds are comprised of 100 close analogs of SR-1815 (a), 3 related compounds in the original screening library (e.g, SR-1821; grey circle), and SR-1815 (reference compound). d Identification of clearly modifiable R-groups derived from structure-activity analysis of SR-1815 analogs shown in (c). Source data are provided as a Source Data file.

Back to article page